Loading...
XTAE
ILX
Market cap181mUSD
Apr 10, Last price  
6,020.00ILS
1D
3.74%
1Q
-19.44%
Jan 2017
13,780.56%
Name

Ilex Medical Ltd

Chart & Performance

D1W1MN
P/E
1,323.62
P/S
72.35
EPS
4.55
Div Yield, %
2.27%
Shrs. gr., 5y
2.20%
Rev. gr., 5y
9.14%
Revenues
920m
-1.13%
461,424,000432,823,000497,495,000518,943,000553,664,000601,134,000633,958,000946,452,0001,060,994,000872,544,000930,890,000920,371,000
Net income
39m
-23.39%
-22,211,00022,103,00031,105,00027,650,00037,403,00046,981,00060,257,000120,621,000197,480,000102,123,00050,885,00038,981,000
CFO
82m
+1.49%
22,268,00079,814,00045,175,00012,768,00075,962,00058,601,00084,887,000182,404,000270,676,00069,739,00080,432,00081,630,000
Dividend
Apr 07, 2024136.45 ILS/sh

Profile

Ilex Medical Ltd engages in marketing, selling, and supporting equipment, disposables, and reagents for laboratories and healthcare establishments in Israel and South Africa. The company offers in vitro diagnostic equipment and reagent systems to hospitals, clinics, and other medical institutions; molecular biology products for cancer screening, retro virus viral load, TB, STDs, and other infectious diseases; and equipment, disposables, and reagents for in vitro fertilization, as well as food and pharma industries. It also distributes and supports nucleic acid testing blood screening solutions to large-scale blood banks; provides pre/post analytics and robotics; and develops, markets, implements, and supports laboratory information systems. In addition, the company offers specialized product range that includes molecular diagnostics, critical care, and immunology products. Ilex Medical Ltd was founded in 1977 and is based in Petah Tikva, Israel.
URL
https://www.ilexmedical.com/
IPO date
Jan 01, 1995
Employees
255
Domiciled in
IL
Incorporated in
IL

Valuation

Title
ILS in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
920,371
-1.13%
930,890
6.69%
872,544
-17.76%
Cost of revenue
730,646
731,161
622,274
Unusual Expense (Income)
NOPBT
189,725
199,729
250,270
NOPBT Margin
20.61%
21.46%
28.68%
Operating Taxes
15,894
18,518
34,618
Tax Rate
8.38%
9.27%
13.83%
NOPAT
173,831
181,211
215,652
Net income
38,981
-23.39%
50,885
-50.17%
102,123
-48.29%
Dividends
(15,266)
(21,442)
(60,000)
Dividend yield
1.82%
3.26%
5.55%
Proceeds from repurchase of equity
(5,716)
(3,487)
BB yield
0.87%
0.32%
Debt
Debt current
12,532
11,880
12,839
Long-term debt
89,849
83,925
88,979
Deferred revenue
25,280
18,390
Other long-term liabilities
13,071
77,681
Net debt
(128,582)
(175,413)
(171,801)
Cash flow
Cash from operating activities
81,630
80,432
69,739
CAPEX
(29,759)
(48,771)
(28,359)
Cash from investing activities
(22,936)
(90,677)
(53,636)
Cash from financing activities
(28,894)
(40,718)
(77,298)
FCF
152,763
176,237
149,104
Balance
Cash
233,626
213,264
224,199
Long term investments
(2,663)
57,954
49,420
Excess cash
184,944
224,674
229,992
Stockholders' equity
581,053
482,213
527,888
Invested Capital
551,240
524,778
450,835
ROIC
32.31%
37.15%
53.02%
ROCE
25.68%
26.65%
36.59%
EV
Common stock shares outstanding
11,171
11,190
11,279
Price
74.89
27.36%
58.80
-38.63%
95.82
5,792.99%
Market cap
836,573
27.14%
657,972
-39.12%
1,080,754
5,791.94%
EV
707,991
482,559
970,746
EBITDA
238,823
247,453
300,309
EV/EBITDA
2.96
1.95
3.23
Interest
2,422
2,655
1,607
Interest/NOPBT
1.28%
1.33%
0.64%